Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manoela Tiago

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Oncogene|January 20, 2022
Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanomaAnna Han, Vivian Chua, Usman Baqai, et al.
Cell Death & Disease|March 27, 2019
CADM1 is a TWIST1-regulated suppressor of invasion and survivalEdward J Hartsough, Michele B Weiss, Shea A Heilman, et al.
Cancer Immunology Research|July 15, 2020
Activation of CD8<sup>+</sup> T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK InhibitorsJessica L F Teh, Dan A Erkes, Phil F Cheng, et al.
Tissue Engineering. Part A|February 20, 2014
Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicinManoela Tiago, Edson Mendes de Oliveira, Carla Abdo Brohem, et al.
Pharmacological Research|July 21, 2016
Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulationSilvana Sandri, Fernanda Faião-Flores, Manoela Tiago, et al.
Pharmacological Research|June 15, 2020
Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistanceSilvana Sandri, Luis R M Watanabe, Erica Aparecida de Oliveira, et al.
Nature Communications|November 5, 2025
Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma modelsConnor A Ott, Timothy J Purwin, Pan-Yu Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal MelanomaJustine S Paradis, Monica Acosta, Robert Saddawi-Konefka, et al.
Plos One|May 3, 2014
A natural bacterial-derived product, the metalloprotease arazyme, inhibits metastatic murine melanoma by inducing MMP-8 cross-reactive antibodiesFelipe V Pereira, Carla A Ferreira-Guimarães, Thaysa Paschoalin, et al.
Cancers|July 14, 2023
Co-Targeting FASN and mTOR Suppresses Uveal Melanoma GrowthAnna Han, Dzmitry Mukha, Vivian Chua, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Oncogene|January 20, 2022
Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanomaAnna Han, Vivian Chua, Usman Baqai, et al.
Cell Death & Disease|March 27, 2019
CADM1 is a TWIST1-regulated suppressor of invasion and survivalEdward J Hartsough, Michele B Weiss, Shea A Heilman, et al.
Cancer Immunology Research|July 15, 2020
Activation of CD8<sup>+</sup> T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK InhibitorsJessica L F Teh, Dan A Erkes, Phil F Cheng, et al.
Tissue Engineering. Part A|February 20, 2014
Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicinManoela Tiago, Edson Mendes de Oliveira, Carla Abdo Brohem, et al.
Pharmacological Research|July 21, 2016
Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulationSilvana Sandri, Fernanda Faião-Flores, Manoela Tiago, et al.
Pharmacological Research|June 15, 2020
Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistanceSilvana Sandri, Luis R M Watanabe, Erica Aparecida de Oliveira, et al.
Nature Communications|November 5, 2025
Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma modelsConnor A Ott, Timothy J Purwin, Pan-Yu Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal MelanomaJustine S Paradis, Monica Acosta, Robert Saddawi-Konefka, et al.
Plos One|May 3, 2014
A natural bacterial-derived product, the metalloprotease arazyme, inhibits metastatic murine melanoma by inducing MMP-8 cross-reactive antibodiesFelipe V Pereira, Carla A Ferreira-Guimarães, Thaysa Paschoalin, et al.
Cancers|July 14, 2023
Co-Targeting FASN and mTOR Suppresses Uveal Melanoma GrowthAnna Han, Dzmitry Mukha, Vivian Chua, et al.
Pageof 3